AXL and hepatocellular carcinoma: Cabozantinib is a multityrosine kinase inhibitor (mTKI) of VEGFR2, c‐Met, Ret, Tie2, and AXL that is approved for patients with advanced stage HCC and is under investigation in combination with immune checkpoint therapy in HCC as well as other tumor types.